AbbVie key products revenues 2021-2022

AbbVie is an international pharmaceutical company with a multitude of pharmaceutical products available. In 2022, once again, the company’s top revenue generating drug was Humira. During that year, Humira generated about 21.2 billion U.S. dollars in revenue for AbbVie. Humira is used to treat several types of autoimmune diseases including certain types of arthritis and Crohn’s disease. The second highest revenue generating drug for the company was Skyrizi, though it generated significantly less revenue that Humira.

AbbVie’s company profile

Abbvie was founded in 2013, originally a spin-off of Abbott Laboratories, and is based out of Chicago, Illinois, in the United States. In recent years the company has experience some growth which can also be seen in their increasing number of employees. The company has also experienced exceptional growth in their yearly revenue earnings. Finally, AbbVie has experienced significant growth in its total assets in recent years. On May 8, 2020, AbbVie completed the acquisition of Allergan plc.

AbbVie’s global positioning

Despite being a young company, it is clear that AbbVie is among the top pharmaceutical companies. AbbVie is placed among other top companies such as Pfizer and Johnson & Johnson in terms of their prescription sales and expenditure on research and development. The company is also among the top pharmaceutical companies in terms of its net profits per employee.